Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
A further investigation using N- and C-terminal-specific β-catenin antibodies on human hepatoblastomas revealed a correlation between full-length versus truncated β-catenin and differentiation status, with embryonal hepatoblastomas expressing full-length β-catenin and fetal hepatoblastomas expressing β-catenin lacking its N terminus.
|
22613727 |
2012 |
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Tumors derived from 56 HBL cases treated with the Japanese Study Group for Pediatric Liver Tumors (JPLT) Protocol-2 were analyzed for oncogenic mutations (missense mutations and interstitial deletions in the third exon) of the CTNNB1 gene-encoding β-catenin and for the expression levels of telomerase reverse transcriptase (TERT).
|
22152854 |
2011 |
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In CTNNB1-mutated hepatoblastoma, expression of GS was only detected in tumour areas with epithelial, not with mesenchymal differentiation.
|
21237236 |
2011 |
Hepatoblastoma
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
Our results also revealed a large subset of HB, 83%, with cytoplasmic expression of tyrosine654-phosphorylated beta-catenin and 30% showing additional nuclear accumulation.
|
21992464 |
2011 |
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
CTD_human |
Differential expression of glutamine synthetase and cytochrome P450 isoforms in human hepatoblastoma.
|
21237236 |
2011 |
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Among human cancers tightly linked to abnormal Wnt/β-catenin signaling, hepatoblastoma (HB) presents with the highest rate (50-90%) of β-catenin mutations.
|
19646548 |
2011 |
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
Deregulation of the APC/beta-catenin pathway occurs in a consistent fraction of hepatoblastomas, with mutations in the APC and beta-catenin genes implicated in familial adenomatous polyposis-associated and sporadic hepatoblastomas, respectively.
|
17962810 |
2008 |
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
This study confirms that beta-catenin deregulation is involved in sporadic hepatoblastoma and also suggests that mismatch repair defects and p53 mutations contribute to this rare liver cancer.
|
17962810 |
2008 |
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
beta-catenin mutation and RASSF1A methylation were found in 22 (56.4%) and 15 (38.5%) of 39 hepatoblastomas, respectively, but SFRPs methylation was not found in any of them.
|
16937357 |
2007 |
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Overexpression of Tbx3 is closely associated with the mutational status of beta-catenin in murine liver tumors induced by Myc as well as in human hepatocellular carcinomas and hepatoblastomas.
|
17283120 |
2007 |
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
To address beta-catenin's capability in maintaining the malignant phenotype in established pediatric HB and HCC cell lines, HuH-6 and HepG2, harboring mutated and overexpressed beta-catenin, we carried out a series of in vitro analyses through a transfection of short interfering RNAs (siRNAs) to generate a loss-of-function model.
|
16465377 |
2006 |
Hepatoblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
A histological examination revealed all HBL cases involving tumors without detectable CTNNB1 gene alterations to show high expression of beta-catenin, thus indicating the accumulation of beta-catenin to be a common event in malignant PLTs, including HBL and hepatocellular carcinoma.
|
16465411 |
2006 |
Hepatoblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Our findings are consistent with a relationship between poor histologic phenotype and beta-catenin activation, indicating the potential utility of targeted gene expression assays to identify molecular events related to the pathogenesis and prognosis of hepatoblastomas.
|
17163162 |
2006 |
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The Wnt/beta-catenin/T-cell factor (Tcf) pathway is aberrantly up-regulated in the majority of colorectal cancers (CRC) and hepatoblastomas due to either an APC or beta-catenin gene mutation.
|
17047077 |
2006 |
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
The upregulation of REG3A and REG1A expression is significantly correlated to the beta-catenin status in 42 HCC and 28 hepatoblastomas characterized for their beta-catenin status.
|
16314847 |
2006 |
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In human liver tumor cells without beta-catenin mutations, Nkd-1 inhibited the Wnt-3a-activated Tcf-responsive-luciferase reporter activity, whereas Nkd-1 in hepatoblastomas with beta-catenin mutations had no antagonistic effect.
|
15958610 |
2005 |
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Although mutations in CTNNB1 were not found in the second hepatoblastoma, nuclear accumulation of beta-catenin was detected.
|
14692643 |
2004 |
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These observations suggest that accumulation of beta-catenin without an additional somatic mutation in the APC gene might be a possible mechanism for tumorigenesis of hepatoblastoma in the FAP families.
|
14654913 |
2004 |
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Recent evidences have suggested that the abnormalities in Wnt signaling pathway, as seen in frequent mutation of the beta-catenin gene, may play a role in the genesis of hepatoblastoma.
|
15221005 |
2004 |
Hepatoblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The beta-catenin mutations are identified in up to 30% of HCC and 80% of hepatoblastoma, suggesting a potential role of beta-catenin in the pathogenesis of liver cancers.
|
14767485 |
2004 |
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Interestingly, activating mutations of the beta-catenin gene have previously been identified in 48% of HBs, and more than 85% of HBs show accumulation of beta-catenin protein as the indicator for an activated pathway.
|
12649343 |
2003 |
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Recently, disregulation of the Wnt/beta-catenin pathway, attributable to abnormalities of the beta-catenin gene, has been reported to be a major event in the development of hepatocellular carcinomas and hepatoblastomas.
|
12203220 |
2002 |
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
To explore the contribution of additional Wnt pathway molecules to hepatocarcinogenesis, we examined beta-catenin, AXIN1 and AXIN2 mutations in 73 HCCs and 27 HBs. beta-catenin mutations were detected in 19.2% (14 out of 73) HCCs and 70.4% (19 out of 27) HBs. beta-catenin mutations in HCCs were primarily point mutations, whereas more than half of the HBs had deletions.
|
12101426 |
2002 |
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
It is therefore concluded that immunohistochemical analysis of beta-catenin might be a useful clinical tool for estimating the prognosis for patients with hepatoblastoma.
|
11276007 |
2001 |
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
According to recent reports describing beta-catenin mutations (BCM) at hot-spot regions involving exon 3 in several types of malignancies including HB, we investigated BCM in 16 HBs classified into different histological types.
|
11666046 |
2001 |